| Risk of natalizumab-associated progressive multifocal leukoencephalopathy G Bloomgren, S Richman, C Hotermans, M Subramanyam, S Goelz, ... New England Journal of Medicine 366 (20), 1870-1880, 2012 | 1404 | 2012 |
| Anti‐JC virus antibodies: implications for PML risk stratification L Gorelik, M Lerner, S Bixler, M Crossman, B Schlain, K Simon, A Pace, ... Annals of neurology 68 (3), 295-303, 2010 | 524 | 2010 |
| Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy T Plavina, M Subramanyam, G Bloomgren, S Richman, A Pace, S Lee, ... Annals of neurology 76 (6), 802-812, 2014 | 465 | 2014 |
| Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations G Shankar, S Arkin, L Cocea, V Devanarayan, S Kirshner, A Kromminga, ... The AAPS journal 16, 658-673, 2014 | 280 | 2014 |
| Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. WG Gutheil, M Subramanyam, GR Flentke, DG Sanford, E Munoz, ... Proceedings of the National Academy of Sciences 91 (14), 6594-6598, 1994 | 186 | 1994 |
| Challenges and approaches for the development of safer immunomodulatory biologics JG Sathish, S Sethu, MC Bielsky, L De Haan, NS French, K Govindappa, ... Nature Reviews Drug Discovery 12 (4), 306-324, 2013 | 178 | 2013 |
| Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. M Subramanyam, WG Gutheil, WW Bachovchin, BT Huber Journal of immunology (Baltimore, Md.: 1950) 150 (6), 2544-2553, 1993 | 177 | 1993 |
| Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY‐1 C Bozic, S Richman, T Plavina, A Natarajan, JV Scanlon, ... Annals of neurology 70 (5), 742-750, 2011 | 170 | 2011 |
| A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk … P Lee, T Plavina, A Castro, M Berman, D Jaiswal, S Rivas, B Schlain, ... Journal of Clinical Virology 57 (2), 141-146, 2013 | 168 | 2013 |
| Taking immunogenicity assessment of therapeutic proteins to the next level IC Büttel, P Chamberlain, Y Chowers, F Ehmann, A Greinacher, R Jefferis, ... Biologicals 39 (2), 100-109, 2011 | 163 | 2011 |
| Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics S Gupta, V Devanarayan, D Finco, GR Gunn III, S Kirshner, S Richards, ... Journal of pharmaceutical and biomedical analysis 55 (5), 878-888, 2011 | 137 | 2011 |
| A novel PEGylated interferon beta‐1a for multiple sclerosis: safety, pharmacology, and biology X Hu, L Miller, S Richman, S Hitchman, G Glick, S Liu, Y Zhu, M Crossman, ... The Journal of Clinical Pharmacology 52 (6), 798-808, 2012 | 129 | 2012 |
| Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies WS Putnam, S Prabhu, Y Zheng, M Subramanyam, YMC Wang Trends in biotechnology 28 (10), 509-516, 2010 | 115 | 2010 |
| Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort T Olsson, A Achiron, L Alfredsson, T Berger, D Brassat, A Chan, G Comi, ... Multiple Sclerosis Journal 19 (11), 1533-1538, 2013 | 113 | 2013 |
| Anti‐JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial C Bozic, M Subramanyam, S Richman, T Plavina, A Zhang, B Ticho European Journal of Neurology 21 (2), 299-304, 2014 | 109 | 2014 |
| Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development A Mikulskis, D Yeung, M Subramanyam, L Amaravadi Journal of immunological methods 365 (1-2), 38-49, 2011 | 96 | 2011 |
| Alefacept selectively promotes NK cell‐mediated deletion of CD45R0+ human T cells JC Cooper, G Morgan, S Harding, M Subramanyam, GR Majeau, ... European journal of immunology 33 (3), 666-675, 2003 | 79 | 2003 |
| Changes to anti-JCV antibody levels in a Swedish national MS cohort C Warnke, R Ramanujam, T Plavina, T Bergström, S Goelz, ... Journal of Neurology, Neurosurgery & Psychiatry 84 (11), 1199-1205, 2013 | 76 | 2013 |
| Human T cells respond to mouse mammary tumor virus-encoded superantigen: V beta restriction and conserved evolutionary features. N Labrecque, H McGrath, M Subramanyam, BT Huber, RP Sekaly The Journal of experimental medicine 177 (6), 1735-1743, 1993 | 75 | 1993 |
| Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients T Plavina, KK Muralidharan, G Kuesters, D Mikol, K Evans, ... Neurology 89 (15), 1584-1593, 2017 | 72 | 2017 |
